PMN (ProMIS Neurosciences) Scaled Net Operating Assets: -0.34 (As of Mar. 2026)


PMN ProMIS Neurosciences Inc PMN
30 GF Score
Price $13.39
! 2 Warning Signs
View Full Analysis

What is ProMIS Neurosciences Scaled Net Operating Assets?

ProMIS Neurosciences PMN +22.42% 30 Scaled Net Operating Assets is -0.34 as of Mar. 2026. GuruFocus rates PMN with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

ProMIS Neurosciences's operating assets for the quarter that ended in Mar. 2026 was $3.56 Mil. ProMIS Neurosciences's operating liabilities for the quarter that ended in Mar. 2026 was $6.69 Mil. ProMIS Neurosciences's Total Assets for the quarter that ended in Dec. 2025 was $9.18 Mil. Therefore, ProMIS Neurosciences's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was -0.34.

ProMIS Neurosciences Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for ProMIS Neurosciences's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProMIS Neurosciences Scaled Net Operating Assets Chart

ProMIS Neurosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.82 -0.41 -1.28 0.23 -0.39

ProMIS Neurosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 -0.36 -0.66 -0.35 -0.34

PMN vs BMEA, ANIX, ATRA: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, ProMIS Neurosciences's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProMIS Neurosciences Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where ProMIS Neurosciences's Scaled Net Operating Assets falls into.


PMN
30GF Score
ProMIS Neurosciences Inc PMN
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ProMIS Neurosciences Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

ProMIS Neurosciences's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(3.032-10.441)/18.911
=-0.39

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=9.182 - 6.15
=3.032

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=10.441 - 0 - 0
=10.441

ProMIS Neurosciences's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(3.564-6.694)/9.182
=-0.34

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=67.412 - 63.848
=3.564

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=6.694 - 0 - 0
=6.694

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -0.34 mean?
ProMIS Neurosciences (PMN) has a Scaled Net Operating Assets of -0.34 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on ProMIS Neurosciences and its competitors.
Is ProMIS Neurosciences' Scaled Net Operating Assets too high?
ProMIS Neurosciences' current Scaled Net Operating Assets is -0.34. Overall, ProMIS Neurosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does ProMIS Neurosciences' Scaled Net Operating Assets compare to BMEA and ANIX?
ProMIS Neurosciences' Scaled Net Operating Assets of -0.34 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on ProMIS Neurosciences and its competitors. ProMIS Neurosciences's current Scaled Net Operating Assets is -0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProMIS Neurosciences stock overvalued right now?
ProMIS Neurosciences (PMN) has a current Scaled Net Operating Assets of -0.34. The current Scaled Net Operating Assets is -0.34. ProMIS Neurosciences' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For ProMIS Neurosciences (PMN), the current Scaled Net Operating Assets is -0.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProMIS Neurosciences Business Description

Other Exchanges 23J:Germany
Address 1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
30GF Score

Get the complete analysis for PMN

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.39
Price